← All trials
NCT07223203
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Dec 27, 2027
- Completion date
- Jun 12, 2031
- First posted
- Oct 31, 2025
- Last posted
- Oct 31, 2025
- Enrollment
- 125
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alnylam PharmaceuticalsLead sponsor
- Alnylam PharmaceuticalsOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.